Objectives: To evaluate the correlations of the combination of undetectable HIV-DNA (,10 copies/10 6 peripheral blood mononuclear cells) and HIV-RNA (,1 copy/mL of plasma) levels and a CD4 cell count of .500 cells/mm 3 (defined as the treatment goal) in a group of 420 antiretroviral treatment (ART) responder patients.
Introduction
Combination antiretroviral treatment (ART) of individuals infected with HIV reduces progression to AIDS and the morbidity and mortality associated with advanced infection. 1 -3 The prognostic power of numerous laboratory markers has been used to monitor disease progression and response to treatment, but no single parameter has been demonstrated to be more efficient than any other in identifying patients presenting a complete viro-immunological response to ART.
Prolonged ART is required to completely suppress viraemia. Lack of treatment adherence and drug toxicity are the most frequent treatment failure-related factors. 4, 5 A number of approaches to treatment regimen simplification have been explored to improve adherence, reduce the risk of virological failure and long-term toxicity and enhance patient quality of life, 6 -9 but it remains difficult to determine the best time for treatment simplification and what parameters are especially useful in defining the category of patients who can most benefit from simplification schemes without incurring a risk of 10 -12 Recently, a trial of patients receiving treatment simplified to darunavir/ritonavir monotherapy indicated a higher risk of failure compared with patients maintained on triple-drug regimens. A multivariate analysis indicated that higher HIV-DNA levels and a plasma viraemia level .1 copy/mL were significantly correlated with simplification treatment failure. 13 With the ultimate aim of identifying the characteristics of the subjects with the best ART response, we have arbitrarily chosen a combination of three laboratory parameters for analysis, as follows: ,10 copies of HIV-DNA/10 6 peripheral blood mononuclear cells (PBMCs), ,1 copy/mL of plasma HIV-RNA and a CD4 cell count of .500 cells/mm 3 . We also evaluated the correlations of the combination of these three markers in a group of 420 ART-responding patients.
Patients and methods

Study design
A cross-sectional, open-label, multicentre trial was conducted in a cohort of 420 HIV-infected subjects retrospectively selected from among those who achieved virological suppression within 6 months of receipt of a firstline therapy and who maintained a plasma HIV-RNA level ,50 copies/ mL, without virological failure, until the follow-up evaluation. A change of the ART, when it occurred, was accepted only if it was due to intolerance or pill burden convenience. Enrolled patients were allowed no more than one viral 'blip' (defined as ,400 HIV-RNA copies/mL) after achieving viral suppression, as determined by frequent blood sampling (at least three times per year).
A blood sample was collected from each patient enrolled in the study. Blood samples collected in EDTA-containing tubes were separated into plasma and cells by Ficoll -Hypaque density gradient centrifugation. Aliquots of plasma and peripheral blood lymphocytes were stored at 2808C until use.
All of the patients had a high level (.95%) of self-reported adherence, and written informed consent was obtained from all of the participants. The Ethics Committee of Tor Vergata University Hospital approved the study.
HIV-1-RNA residual plasma viraemia quantification
Plasma obtained from blood samples collected in EDTA was frozen at 2808C within 4 h of collection and kept at this temperature until tested. Residual viraemia was quantified by an ultrasensitive method based on a modified protocol that used the Amplicor HIV-1 Monitor Kit v1.5 (Roche Molecular Systems, Branchburg, NJ, USA), with a limit of detection of 1 copy/mL. Modifications included pelleting of the virus from ≥2 mL of plasma at 200000 g at 48C for 1 h. The HIV-RNA pellet was extracted, adding half of the normal volume of quantification standard, resuspended in 1/8 of standard volume diluents and assayed by reverse transcription and PCR amplification with a standard protocol. PCR and detection steps followed the manufacturer's protocol. For the calculation of HIV-RNA copy number the correction factor was adjusted according to the modified volume of internal quantification standard.
Cell-associated HIV-1-DNA quantification
Blood collected in EDTA was separated into plasma and cells by FicollHypaque density gradient centrifugation. Next, dry pellets made up of 2×10 6 PBMCs were stored at 2208C until used. To quantify the total proviral HIV-DNA copy number in PBMCs, the real-time TaqMan protocol published by Viard et al.
14 was adapted for a LightCycler (Roche Molecular Biochemicals, Indianapolis, IN, USA). The cell line 8E5, containing one integrated HIV-DNA copy per cell, was used to build a standard curve of seven dilutions in duplicate (75 000, 37500, 3750, 375, 37.5, 3.75 and 1.87 copies). The PCR sensitivity was 1 copy of HIV-DNA per reaction (1 copy per reaction is approximately 10 copies/10 6 PBMCs). The HIV-DNA target was hybridized with a TaqMan 
Statistical analysis
Unadjusted ORs and 95% CIs from univariate logistic regression models were used to summarize the bivariate associations between each of the demographic, clinical and viro-immunological variables and the different antiretroviral regimens in use with ,10 copies/10 6 HIV-DNA in PBMCs, ,1 copy/mL of plasma HIV-RNA and a CD4 cell count of .500 cells/mm 3 . Multivariate logistic regression analysis was used to estimate the adjusted OR and 95% CI of the combination of the three parameters (,10 copies/10 6 HIV-DNA in PBMCs, ,1 copy/mL of plasma HIV-RNA and a CD4 cell count of .500 cells/mm 3 ). The covariates were selected on the basis of literature data and the significance of univariate and bivariate analyses. Logistic regression analyses were performed to identify potential confounders. Statistical analyses were performed using the SAS statistical package (SAS Institute Inc., Cary, NC, USA).
Results
The general characteristics of the study population are reported in Table 1 . A total of 420 HIV-1-infected patients, receiving firstline ART, with HIV-1 viral loads persistently ,50 copies/mL and without a history of virological failure were included. Out of the total study population, 118 (28.1%) patients were female. The median participant age was 42.0 years (IQR 36.4 -47 years). Unprotected heterosexual relationships were the most common risk factor, observed in 45.9% of cases. Median nadir CD4 cell count was 232 cells/mm 3 The demographic and viro-immunological characteristics of the patients with .10 or ,10 HIV-DNA copies/10 6 PBMCs are listed in Table 2 . Proviral DNA was undetectable (,10 copies/ 10 6 PBMCs) in 70 patients (16.6%) . No significant differences were found between the two groups of patients, but heterosexual relationships were the most frequent risk factor in the group of patients with an undetectable level of HIV-DNA (P¼ 0.01), and homosexual patients more frequently had a detectable HIV-DNA level (P ¼ 0.07). Moreover, the patients with an undetectable HIV-DNA level were on ART for a longer period. A significant correlation was found between undetectable HIV-DNA levels and residual viraemia (P¼ 0.0001). In particular, a significantly higher number of patients with undetectable HIV-DNA levels had undetectable HIV plasma viraemia compared with patients with .10 HIV-DNA copies/10 6 PBMCs (62.8% versus 30.5%, P,0.0001).
The demographic and viro-immunological characteristics of the patients with .1 (n¼269, 64%) or ,1 (n¼ 151, 35.9%) copy/mL of plasma HIV-RNA are listed in Table 3 . The patients with undetectable residual viraemia had a higher CD4 cell count nadir (P,0.001) and lower HIV-RNA viraemia at the start of treatment (P ¼ 0.0016); moreover, these patients were more frequently treated with NNRTIs (P ¼ 0.008), particularly nevirapine (P,0.001), than patients with detectable levels of HIV-RNA. A significantly higher number of patients presenting with undetectable viraemia had an undetectable HIV-DNA level compared with patients with HIV-RNA levels .1 copy/mL (29.1% versus 9.6%, P,0.0001).
Twenty-six out of 420 patients (6.2%) presented a combination of undetectable HIV-RNA plasma levels (,1 copy/mL) and cellular HIV-DNA levels (,10 copies/10 6 PBMCs) and .500 CD4 cells/mm 3 . These patients were considered to have the best ART response, and the association of the three parameters was defined as the treatment goal. The comparison of these patients with the remainder of the study population is shown in Table 4 .
The patients reaching the treatment goal had a significantly higher CD4 cell count nadir (P ¼0.019), lower plasma HIV-RNA values at the beginning of therapy (P ¼ 0.0006) and longer ART periods (P ¼ 0.013); moreover, they were more frequently treated with nevirapine (P ¼ 0.013) compared with the 394 patients not reaching the treatment goal.
Multivariate analyses, adjusted for multiple confounding variables, are presented in Table 5 . Reaching the treatment goal (.500 CD4 cells/mm 3 , ,1 copy HIV-RNA/mL, ,10 copies HIV-DNA/10 6 PBMCs) was confirmed to be independently related to the nadir CD4 cell count (OR 3.86, 95% CI 1.47 -10.16, P ¼ 0.006), the duration of treatment (OR 1.07, 95% CI 1.02-1.12, P ¼0.004) and the receipt of current nevirapine therapy (OR 2.59, 95% CI 1.07 -6.28, P¼ 0.034).
Discussion
In this cross-sectional multicentre study of 420 HIV-1-infected subjects with no history of virological failure who received ART treatment for .2 years, 26 (6.2%) patients presented with a CD4 cell count .500 cells/mm 3 , undetectable plasma HIV-RNA levels (,1 copy/mL) and undetectable cellular HIV-DNA levels (,10 copies/10 6 PBMCs). Higher nadir CD4 cell count, the duration of therapy and the use of nevirapine were independently related to having all three characteristics.
Several studies with varying results have reported on the prognostic strength of HIV-DNA. 15 -24 HIV-DNA is a strong predictor of HIV-1 disease progression, and undetectable HIV-DNA levels have been related to low levels of HIV-DNA pre-therapy, duration of effective ART, high CD4 count at the start of therapy or treatment in the acute infection phase. 16 -24 In our study, 16.6% of the patients receiving effective highly active antiretroviral therapy (HAART) regimens presented undetectable levels of HIV-DNA, and this characteristic was correlated with undetectable HIV-RNA levels and a prolonged ART period.
In a longitudinal study of a cohort of HIV-seropositive subjects evaluated before and at definite timepoints after the beginning of treatment, the achievement of HIV-RNA levels ,2.5 copies/ mL was correlated with low cellular HIV-DNA levels and low plasma viraemia at the beginning of therapy and with high CD4 cell count at baseline and follow-up. 19 Approximately 36% (151/420) of the subjects in our study cohort had HIV-RNA levels ,1 copy/mL. This finding was significantly related to a higher CD4 cell count nadir and, according to the aforementioned longitudinal study, lower HIV-RNA viraemia at the start of treatment and NNRTI use, particularly nevirapine. The superior virological efficacy of nevirapine compared with efavirenz could be related to the greater tissue penetration of the drug. One might suppose that some of the virions remaining measurable Sarmati et al.
by ultrasensitive assay are produced in certain body compartments where nevirapine is able to penetrate and exert a stronger inhibitory effect compared with either efavirenz or protease inhibitors. Interestingly, a significant majority of patients with an HIV-RNA level ,1 copy/mL also had undetectable HIV-DNA levels. In previous cross-sectional studies of cohorts of virologically suppressed ART recipients, nevirapine use was the only independent factor associated with virological suppression. Undetectable HIV-RNA and HIV-DNA levels during ART 2935 JAC A study examining the correlation between cellular HIV-DNA and HIV-RNA levels below laboratory testing thresholds 27 demonstrated that there is a strict correlation between sustained undetectable HIV-RNA levels and a low number of cells carrying HIV-DNA. Similar data were obtained in another study, 19 which substantially confirms the predictive capacity of HIV-DNA load for the long-term virological success of ART.
25,26
On the basis of laboratory parameters usually used in the monitoring of antiretroviral therapy, we selected a subset of the studied population with the best viro-immunological characteristics of response to ART. These characteristics were arbitrarily chosen to be CD4 cell count .500 cells/mm 3 , HIV-DNA ,10 copies/10 6 PBMCs and HIV-RNA ,1 copy/mL. Only 26 patients out of 420 (6.2%) possessed all three characteristics. A multivariate analysis indicated that possessing all three characteristics was significantly related to nevirapine use, duration of treatment and higher CD4 nadir cell count.
The use of NNRTIs, particularly nevirapine, has been associated with a better virological performance in several studies. 22, 25, 27, 28 This relationship was originally described in studies that compared NNRTI regimens with unboosted PI regimens, such as the FIRST, ACTG 384 and INITIO clinical trials. 29 -31 In the ACTG 5142 clinical trial comparing efavirenz-versus lopinavir-including regimens in naive patients, a significantly better virological outcome was observed at week 96 in patients treated with NNRTIs (P ¼ 0.003). 32 In a previous publication, 23 it was demonstrated that the lowest level of residual viraemia is independently related to the use of NNRTIs, and this result was confirmed by subsequently published studies 22, 25 and in a recent publication on 1214 patients in which subjects treated with an NNRTI-based ART had a higher chance of maintaining viraemia ,3 copies/ mL. 28 Certain authors have attributed this finding to the better penetration of nevirapine in extravascular compartments, such as the CNS, genital tract and breast milk. The good penetration of nevirapine in these areas likely contributes to the local control of viral replication in sanctuaries that are typically spared from the action of other antiretroviral drugs. There are no data on the influence of NNRTI use on HIV-DNA levels, but an association was proposed between the use of PIs and lower levels of HIV-DNA. 22 The timing of the ART initiation and ART duration are related to the control of HIV replication. Our results demonstrate a significant correlation between combined high CD4 count at nadir and a prolonged effective ART period with undetectable HIV-DNA and HIV-RNA levels, suggesting more efficient virological control following earlier therapy. A correlation between undetectable HIV-DNA levels and the early initiation of ART has been demonstrated in several studies. The correlation between undetectable HIV-DNA levels and ART treatment administered during the primary phase of infection was demonstrated in a longitudinal study on a cohort of HIV-infected people evaluated Sarmati et al.
before the initiation of ART and after the virological response to the treatment. 19, 33 Moreover, in a previous study we demonstrated HIV-DNA reduction to undetectable levels in patients who began treatment with a CD4 cell count .500 cells/mm 3 . 20 The rate of HIV-DNA load decline has been clearly associated with the long-term success of HAART, 34 -36 and in a group of virological responder patients undetectable HIV-DNA values were independently associated with a prolonged ART duration. 21 The main limitation of the study is the cross-sectional design and the lack of HIV-DNA levels prior to therapy because we cannot exclude that they could have influenced the results obtained.
In conclusion, only a few subjects from our cohort of responder ART subjects presented the combination of three laboratory markers that identified them as full responders. These results allowed us to consider the ART virological population as a heterogeneous group of patients in which only a limited number of subjects completely achieved the parameters associated with immunological and virological success. Full response was strictly related to specific characteristics: therapy duration, high CD4 cell count nadir and nevirapine use. The combination of the three aforementioned laboratory parameters may be useful in the evaluation of response to treatment as a guarantee of good control of the infection and should be carefully considered, especially in the selection of patients for possible simplification regimens. 
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